A first-in-class, allosteric, and highly selective for the treatment of refractory epilepsy, advancing through critical IND-enabling studies and Phase 1/2 clinical trials. Approximately 30% of epilepsy patients are refractory to current treatments, and over half reporting debilitating side effects. Our candidate is uniquely positioned to address this gap by offering a trifecta of potential therapeutic benefits: seizure control, pro-cognitive effects, and a psychiatric-neutral profile. Preclinical data is extensive and compelling, demonstrating broad-spectrum anti-seizure efficacy across multiple models. The asset has promising pharmacokinetics, CNS penetration, and a strategic plan designed to achieve key value-inflection milestones.